NO331985B1 - Fremgangsmate for fremstilling av 5-[(R)(5,6-dietyl-indan-2-ylamino)-1-hydroksyetyl]-8-hydroksy-(1H)-kinolin-2-on-salt som er nyttig som adrenoreseptoragonist, samt mellomprodukter - Google Patents

Fremgangsmate for fremstilling av 5-[(R)(5,6-dietyl-indan-2-ylamino)-1-hydroksyetyl]-8-hydroksy-(1H)-kinolin-2-on-salt som er nyttig som adrenoreseptoragonist, samt mellomprodukter Download PDF

Info

Publication number
NO331985B1
NO331985B1 NO20054452A NO20054452A NO331985B1 NO 331985 B1 NO331985 B1 NO 331985B1 NO 20054452 A NO20054452 A NO 20054452A NO 20054452 A NO20054452 A NO 20054452A NO 331985 B1 NO331985 B1 NO 331985B1
Authority
NO
Norway
Prior art keywords
quinolin
formula
hydroxy
salt
diethyl
Prior art date
Application number
NO20054452A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054452D0 (no
NO20054452L (no
Inventor
Olivier Lohse
Caspar Vogel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927689&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO331985(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20054452D0 publication Critical patent/NO20054452D0/no
Publication of NO20054452L publication Critical patent/NO20054452L/no
Publication of NO331985B1 publication Critical patent/NO331985B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44Palladium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO20054452A 2003-02-28 2005-09-26 Fremgangsmate for fremstilling av 5-[(R)(5,6-dietyl-indan-2-ylamino)-1-hydroksyetyl]-8-hydroksy-(1H)-kinolin-2-on-salt som er nyttig som adrenoreseptoragonist, samt mellomprodukter NO331985B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45094503P 2003-02-28 2003-02-28
PCT/EP2004/001981 WO2004076422A1 (en) 2003-02-28 2004-02-27 Process for preparing 5-‘(r)-2-(5,6-diethyl-indian-2-ylamino)-1-hydroxy-ethyl!-8-hydroxy-(1h)-quinolin-2-one salt, useful as an adrenoceptor agonist

Publications (3)

Publication Number Publication Date
NO20054452D0 NO20054452D0 (no) 2005-09-26
NO20054452L NO20054452L (no) 2005-11-28
NO331985B1 true NO331985B1 (no) 2012-05-21

Family

ID=32927689

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054452A NO331985B1 (no) 2003-02-28 2005-09-26 Fremgangsmate for fremstilling av 5-[(R)(5,6-dietyl-indan-2-ylamino)-1-hydroksyetyl]-8-hydroksy-(1H)-kinolin-2-on-salt som er nyttig som adrenoreseptoragonist, samt mellomprodukter

Country Status (30)

Country Link
US (1) US7534890B2 (es)
EP (1) EP1599450B1 (es)
JP (1) JP4802089B2 (es)
KR (1) KR101076929B1 (es)
CN (1) CN100363349C (es)
AR (1) AR043406A1 (es)
AT (1) ATE434609T1 (es)
AU (1) AU2004215647B2 (es)
BR (1) BRPI0407904B1 (es)
CA (1) CA2517033C (es)
CL (1) CL2004000381A1 (es)
CY (1) CY1109442T1 (es)
DE (1) DE602004021675D1 (es)
DK (1) DK1599450T3 (es)
EC (1) ECSP055977A (es)
ES (1) ES2326974T3 (es)
HK (1) HK1086255A1 (es)
IL (1) IL170138A (es)
MX (1) MXPA05009156A (es)
MY (1) MY142491A (es)
NO (1) NO331985B1 (es)
NZ (1) NZ541727A (es)
PE (1) PE20040956A1 (es)
PL (1) PL213932B1 (es)
PT (1) PT1599450E (es)
RU (1) RU2332405C2 (es)
SI (1) SI1599450T1 (es)
TW (1) TWI324150B (es)
WO (1) WO2004076422A1 (es)
ZA (1) ZA200506060B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050211A1 (es) * 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
BRPI0409198A (pt) * 2003-04-04 2006-05-02 Novartis Ag derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
DK2044025T3 (da) 2006-06-30 2013-01-14 Novartis Ag Quinolinonderivater samt farmaceutiske sammensætninger deraf
JP2010520188A (ja) 2007-02-28 2010-06-10 シプラ・リミテッド カルモテロールの異性体を調製する方法
WO2011056929A1 (en) * 2009-11-04 2011-05-12 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
US8680303B2 (en) 2010-03-01 2014-03-25 Massachusetts Institute Of Technology Epoxidation catalysts
WO2013132514A2 (en) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
WO2014008639A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 制备茚达特罗的方法
CN104379566B (zh) * 2012-07-11 2016-08-24 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
WO2014044288A1 (en) * 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
EP3138837B1 (en) 2012-09-21 2021-11-24 Crystal Pharma, S.A.U. Indacaterol free base in solid form
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
ES2626829T3 (es) * 2013-03-27 2017-07-26 Laboratorios Lesvi, S.L. Procedimiento para la fabricación de (R)-5[2-(5,6-dietil-indan-2-ilamino)-1-hidroxietil]-8-hidroxi-(1H)-quinolin-2-ona
WO2015104718A2 (en) 2014-01-09 2015-07-16 Davuluri, Ramamohan Rao A novel process for preparation of indacaterol or its pharmaceutically acceptable salts
WO2016027283A2 (en) 2014-08-22 2016-02-25 Reddy G Pratap A process for preparing indacaterol and salts thereof
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
WO2016161956A1 (zh) * 2015-04-09 2016-10-13 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
US20190185461A1 (en) * 2015-07-21 2019-06-20 Sichuan Haisco Pharmaceutical Co., Ltd. Benzocyclic derivative having b2-receptor agonist activity and m3-receptor antagonist activity and medical use thereof
WO2017055506A1 (en) 2015-09-29 2017-04-06 Laboratorios Lesvi, S.L. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl] -8-hydroxy-1h-quinolin-2-one l-tartrate
CN107021921A (zh) * 2016-02-02 2017-08-08 常州爱诺新睿医药技术有限公司 一种茚达特罗中间体的盐及其制备方法
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN108101841B (zh) * 2016-11-24 2021-04-06 江苏恒瑞医药股份有限公司 一种制备茚达特罗或其盐的方法
CN108264483A (zh) * 2016-12-31 2018-07-10 天津金耀集团有限公司 一种马来酸茚达特罗的制备方法
CN109516974B (zh) * 2017-09-19 2022-05-27 南京圣和药业股份有限公司 取代嘧啶类pi3k抑制剂的制备方法
WO2019135101A1 (en) 2018-01-02 2019-07-11 Deva Holding Anonim Sirketi A process for preparation of 5-(2-(substituted-amino)-1-hydroxyethyl)-8-(substituted-oxy) quinolin-2(1h)-one
CN109721534B (zh) * 2018-09-25 2022-05-20 四川海思科制药有限公司 一种马来酸茚达特罗中间体及其制备方法和用途
CN109988111A (zh) * 2019-05-06 2019-07-09 淮北师范大学 一种马来酸茚达特罗的杂质及其合成方法
CN110128339B (zh) * 2019-05-31 2022-03-08 苏州芝宇生物科技有限公司 一种茚达特罗及其盐衍生物的合成方法和合成用中间体
CN113731406B (zh) * 2021-10-12 2023-07-28 南京工业大学 一种提高钯碳活性加氢脱除保护基的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU2004215647B2 (en) 2006-12-21
ECSP055977A (es) 2006-01-16
AR043406A1 (es) 2005-07-27
PT1599450E (pt) 2009-08-31
RU2332405C2 (ru) 2008-08-27
PE20040956A1 (es) 2005-01-20
JP4802089B2 (ja) 2011-10-26
NO20054452D0 (no) 2005-09-26
TW200505864A (en) 2005-02-16
CN1753874A (zh) 2006-03-29
WO2004076422A1 (en) 2004-09-10
EP1599450B1 (en) 2009-06-24
SI1599450T1 (sl) 2009-12-31
NO20054452L (no) 2005-11-28
MXPA05009156A (es) 2005-10-20
MY142491A (en) 2010-11-30
KR101076929B1 (ko) 2011-10-26
DK1599450T3 (da) 2009-10-05
JP2006519206A (ja) 2006-08-24
CY1109442T1 (el) 2014-08-13
CL2004000381A1 (es) 2005-01-14
RU2005129547A (ru) 2007-04-10
US7534890B2 (en) 2009-05-19
DE602004021675D1 (de) 2009-08-06
ZA200506060B (en) 2006-07-26
PL378358A1 (pl) 2006-03-20
ES2326974T3 (es) 2009-10-22
HK1086255A1 (en) 2006-09-15
BRPI0407904A (pt) 2006-02-14
EP1599450A1 (en) 2005-11-30
AU2004215647A1 (en) 2004-09-10
CN100363349C (zh) 2008-01-23
KR20050105258A (ko) 2005-11-03
ATE434609T1 (de) 2009-07-15
IL170138A (en) 2011-09-27
TWI324150B (en) 2010-05-01
CA2517033C (en) 2011-11-15
CA2517033A1 (en) 2004-09-10
NZ541727A (en) 2008-07-31
BRPI0407904B1 (pt) 2016-09-20
PL213932B1 (pl) 2013-05-31
US20060252794A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
NO331985B1 (no) Fremgangsmate for fremstilling av 5-[(R)(5,6-dietyl-indan-2-ylamino)-1-hydroksyetyl]-8-hydroksy-(1H)-kinolin-2-on-salt som er nyttig som adrenoreseptoragonist, samt mellomprodukter
CA2373834C (en) A process for the production of thiazolidine
AU2015364537A1 (en) Process for the preparation of a diarylthiohydantoin compound
WO2009073462A1 (en) Process for the preparation of 5-cyclopropyl-5, 11-dihydro (1) benzoxepino (3, 4-b) -pyridin-5-ol using tmeda
CA2711645C (en) Process for the preparation of 8-methoxy-quinolone-carboxylic acids
US20080275265A1 (en) Process for the Preparation of (Aminoalkylamino)Alkyl Halides and Conversion to Amifostine
RU2339621C2 (ru) Способ получения 5-(альфа-галогенацетил)-8-(замещенный окси)-(1н)-хинолин-2-онов
CN111087394A (zh) 一种2,9位取代的4-卤代-1,10-邻菲啰啉的合成方法
CA2368815A1 (en) Novel synthesis and crystallization of piperazine ring-containing compounds
KR20140034807A (ko) 7-클로로-4-(피페라진-1-일)-퀴놀린의 합성을 위한 신규 방법
US6545149B2 (en) Synthesis and crystallization of piperazine ring-containing compounds
CA2915841C (en) Method for the preparation of (1,2,4)-triazolo(4,3-a)pyridines
US20040176591A1 (en) Novel synthesis and crystallization of peperazine ring-containing compounds
JP4752121B2 (ja) ニトリル誘導体の製造方法、その中間体および中間体の製造方法
Erkin et al. 4-arylamino-2-(2-acetoxyethyl) amino-6-methylpyrimidines: Synthesis, deacetylation, and biological activity
JPH052673B2 (es)
KR20090076081A (ko) 트로스피움 클로라이드의 제조방법
AU2005201117A1 (en) Novel synthesis and crystallization of piperazine ring-containing compounds